The obesity-drug race is becoming less about losing weight and more about keeping it off.
Why it matters: As more GLP-1 drugs deliver eye-popping results, the next winners may be determined by convenience, affordability and whether patients keep taking them long enough to benefit.
The Food and Drug Administration on Tuesday will issue draft guidance for how companies developing cell and gene therapies can rely on existing scientific knowledge to avoid unnecessary tests and speed up the development process, the agency exclusively told Axios.
Why it matters: The move could be seen as an olive branch to the drug industry and the rare disease community in the wake of former commissioner Marty Makary's departure. But it still will all come down to how the guidance is implemented.
A new bid to fix the process for resolving surprise billing disputes may not make a dent in the massive backlog of cases.
Why it matters: Providers and insurers have been sparring over how to settle claims for out-of-network services almost from the moment Congress protected privately insured patients from getting stuck with huge, unexpected costs.
